Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2015)
Pediatrics DigestPediatrics, 135
Desrosiers (2014)
361Clinical Chemistry, 60
Schlienz (2017)
232Journal of Analytical Toxicology, 42
B. Pomahačová, F. Kooy, R. Verpoorte (2009)
Cannabis smoke condensate III: The cannabinoid content of vaporised Cannabis sativaInhalation Toxicology, 21
R. Brenneisen, P. Meyer, H. Chtioui, M. Saugy, M. Kamber (2010)
Plasma and urine profiles of Δ9-tetrahydrocannabinol and its metabolites 11-hydroxy-Δ9-tetrahydrocannabinol and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletesAnalytical and Bioanalytical Chemistry, 396
G. Ellis, M. Mann, B. Judson, N. Schramm, Agop Tashchian (1985)
Excretion patterns of cannabinoid metabolites after last use in a group of chronic usersClinical Pharmacology & Therapeutics, 38
(2015)
High school students? use of electronic cigarettes to vaporize cannabisPediatrics, 136
Morean (2015)
611Pediatrics, 136
Huestis (1998)
445Journal of Analytical Toxicology, 22
Matthew Newmeyer, Madeleine Swortwood, Allan Barnes, O. Abulseoud, K. Scheidweiler, M. Huestis (2016)
Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake.Clinical chemistry, 62 12
Lindgren (1981)
208Psychopharmacology, 74
J. Manno, B. Manno, P. Kemp, D. Alford, I. Abukhalaf, M. McWilliams, F. Hagaman, M. Fitz-Gerald (2001)
Temporal Indication of Marijuana Use Can Be Estimated From Plasma and Urine Concentrations of Δ9-Tetrahydrocannabinol, 11-Hydroxy-Δ9-Tetrahydrocannabinol, and 11-Nor-Δ9-Tetrahydrocannabinol-9-Carboxylic AcidJournal of Analytical Toxicology, 25
Tory Spindle, E. Cone, N. Schlienz, John Mitchell, G. Bigelow, R. Flegel, Eugene Hayes, R. Vandrey (2018)
Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use CannabisJAMA Network Open, 1
Macdonald (2010)
408Addiction (Abingdon, England), 105
Goodwin (2008)
562Journal of Analytical Toxicology, 32
Brenneisen (2010)
2493Analytical and Bioanalytical Chemistry, 396
Tory Spindle, E. Cone, N. Schlienz, John Mitchell, G. Bigelow, R. Flegel, Eugene Hayes, R. Vandrey (2019)
Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid.Journal of analytical toxicology, 43 4
R. NIEDBALA, K. Kardos, D. Fritch, S. Kardos, Tiffany Fries, Joe Waga, James Robb, E. Cone, S. Niedbala (2001)
Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana.Journal of analytical toxicology, 25 5
Schwartz (1985)
1093American Journal of Diseases of Children, 139
Sobell (1992)
41
Ellis (1985)
572Clinical Pharmacology & Therapeutics, 38
M. Huestis, B. Blount, Daniel Milan, Matthew Newmeyer, J. Schroeder, Michael Smith (2019)
Correlation of creatinine- and specific gravity-normalized free and glucuronidated urine cannabinoid concentrations following smoked, vaporized, and oral cannabis in frequent and occasional cannabis users.Drug testing and analysis
Dustin Lee, Benjamin Crosier, J. Borodovsky, J. Sargent, A. Budney (2016)
Online survey characterizing vaporizer use among cannabis users.Drug and alcohol dependence, 159
M. Huestis, J. Mitchell, E. Cone (1996)
Urinary excretion profiles of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol in humans after single smoked doses of marijuana.Journal of analytical toxicology, 20 6
E. Johansson, M. Halldin (1989)
Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking.Journal of analytical toxicology, 13 4
L. Sobell, M. Sobell (1992)
Timeline Follow-Back A Technique for Assessing Self-Reported Alcohol Consumption
J. Lindgren, A. Ohlsson, S. Agurell, L. Hollister, H. Gillespie (2004)
Clinical effects and plasma levels of Δ9-Tetrahydrocannabinol (Δ9-THC) in heavy and light users of cannabisPsychopharmacology, 74
Pomahacova (2009)
1108Inhalation Toxicology, 21
Johansson (1989)
218Journal of Analytical Toxicology, 13
M. Huestis, E. Cone (1998)
Differentiating new marijuana use from residual drug excretion in occasional marijuana users.Journal of analytical toxicology, 22 6
(1992)
citation_publisher=Humana Press, Totowa, NJ; Timeline Follow-Back. In Measuring Alcohol Consumption
Cone (2014)
1Journal of Analytical Toxicology, 39
Lowe (2009)
24Drug and Alcohol Dependence, 105
E. Cone, G. Bigelow, Evan Herrmann, John Mitchell, C. Lodico, R. Flegel, R. Vandrey (2015)
Non-smoker exposure to secondhand cannabis smoke. I. Urine screening and confirmation results.Journal of analytical toxicology, 39 1
(2018)
Acute effects of smoked and vaporized cannabis in healthy adults who infrequently use cannabis: A cross-over trialJAMA Network Open, 1
Spindle (2018)
e184841JAMA Network Open, 1
Niedbala (2001)
289Journal of Analytical Toxicology, 25
(2017)
Mandatory guidelines for federal workplace drug testing programsFederal Register, 82
F. Barrett, N. Schlienz, Natalie Lembeck, M. Waqas, R. Vandrey (2018)
“Hallucinations” Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic DrugsCannabis and Cannabinoid Research, 3
Spindle (2019)
233Journal of Analytical Toxicology, 43
Wadsworth (2006)
14Journal of Psychopharmacology, 20
Lee (2016)
227Drug and Alcohol Dependence, 159
Nathalie Desrosiers, Dayong Lee, M. Concheiro-Guisan, K. Scheidweiler, D. Gorelick, M. Huestis (2014)
Urinary cannabinoid disposition in occasional and frequent smokers: is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers?Clinical chemistry, 60 2
Barrett (2018)
85Cannabis and Cannabinoid Research, 3
Ross Lowe, Tsadik Abraham, W. Darwin, R. Herning, J. Cadet, M. Huestis (2009)
Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.Drug and alcohol dependence, 105 1-2
D. Bush
Department of Health and Human Services Substance Abuse and Mental Health Services Administration Mandatory Guidelines for Federal Workplace Drug Testing Programs
R. Goodwin, W. Darwin, C. Chiang, M. Shih, Shou-Hua Li, M. Huestis (2008)
Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence.Journal of analytical toxicology, 32 8
(1992)
M.,.B. Timeline Follow-Back
S. Macdonald, W. Hall, P. Roman, T. Stockwell, Michelle Coghlan, Sverre Nesvaag (2010)
Testing for cannabis in the work-place: a review of the evidence.Addiction, 105 3
Substance Abuse and Mental Health Services Administration (SAMHSA) (2017)
7920Federal Register, 82
Huestis (1996)
441Journal of Analytical Toxicology, 20
Manno (2001)
538Journal of Analytical Toxicology, 25
Newmeyer (2016)
1579Clinical Chemistry, 62
N. Schlienz, E. Cone, Evan Herrmann, Natalie Lembeck, John Mitchell, G. Bigelow, R. Flegel, C. Lodico, Eugene Hayes, R. Vandrey (2018)
Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults.Journal of analytical toxicology, 42 4
R. Schwartz, G. Hayden, M. Riddile (1985)
Laboratory detection of marijuana use. Experience with a photometric immunoassay to measure urinary cannabinoids.American journal of diseases of children, 139 11
E. Wadsworth, Sussanna Moss, Sharon Simpson, Andrew Smith (2006)
Cannabis use, cognitive performance and mood in a sample of workersJournal of Psychopharmacology, 20
As cannabis has become more accessible, use of alternative methods for cannabis administration such as vaporizers has become more prevalent. Most prior controlled pharmacokinetic evalua- tions have examined smoked cannabis in frequent (often daily) cannabis users. This study charac- terized the urinary excretion profile of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH), the primary analytical outcome for detection of cannabis use, among infrequent cannabis users fol- lowing controlled administration of both smoked and vaporized cannabis. Healthy adults (N = 17), with a mean of 398 (range 30–1,825) days since last cannabis use, smoked and vaporized cannabis containing 0, 10, and 25 mg of Δ9-tetrahydrocannabinol (THC) across six outpatient sessions. Urinary concentrations of THCCOOH were measured at baseline and for 8 h after cannabis admin- istration. Sensitivity, specificity, and agreement between three immunoassays (IA) for THCCOOH (with cutoffs of 20, 50, and 100 ng/mL) and gas chromatography-mass spectrometry (GC/MS) results (confirmatory concentration of 15 ng/mL) were assessed. THCCOOH concentrations peaked 4–6 h after cannabis administration. Median maximum concentrations (Cmax) for THCCOOH were qualitatively higher after administration of vaporized cannabis compared to equal doses of smoked cannabis. Urine THCCOOH concentrations were substantially lower in this study relative to prior examinations of experienced cannabis users. The highest
Journal of Analytical Toxicology – Oxford University Press
Published: Jan 7, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.